ACRS Aclaris Therapeutics, Inc. Insider Trading

ACRS director sells 300k shares near 52-week highs amid unprofitable operations

A director at Aclaris Therapeutics executed a substantial sale of 300,000 shares, cashing out approximately $1.36 million. The timing is noteworthy—the stock is trading just below its 52-week high after rallying sharply over the past month, suggesting the insider capitalized on recent momentum. However, the company's fundamentals paint a concerning picture: Aclaris is unprofitable with significant quarterly losses and minimal revenue, indicating the business is not yet generating sustainable earnings. This creates a mixed signal—the insider is selling strength on the chart, but selling weakness in the company's operational reality. The sale itself is material in absolute terms but represents only a modest portion of the director's holdings, which limits what we can infer about confidence. Investors should investigate whether management expects near-term headwinds or if this is simply opportunistic liquidity-taking during a favorable price window.

10% owner Leonard Braden Michael bought 373,569 shares at blended $1.27 (Aug 2024) in unprofitable ACRS; stock down -87.4% from $9.85 high.

Leonard Braden Michael, a 10% owner at Aclaris Therapeutics, purchased 373,569 shares across two transactions totaling $472,756.74 at a blended average price of $1.27. The timing is notable: these purchases occurred on August 2 and August 5, 2024, following a sharp decline—the stock currently trades 87.4% below its 52-week high of $9.85 and the insider's five prior purchases at ACRS all occurred within the preceding two weeks (July 18–31). Aclaris is unprofitable (latest quarter net income −$16.9M on $2.4M revenue) with a market cap of $88.4M, indicating this is a microcap company under financial stress. Across his broader trading history, Michael's open-market buys show an average 30-day return of +16.6%, but his same-ticker timing at ACRS shows no measurable 90-day outcomes yet, and prior trades remain sub-90-day and therefore not yet evaluable. The rapid-fire purchase pattern over 15 days suggests sustained conviction, though the outcome and rationale remain to be confirmed.

10% Owner Leonard Braden Michael buys 273,730 shares ($359.0K) at ACRS over 2 days; stock -86.4% from 52-week high; company posting -$16.9M net loss.

Leonard Braden Michael executed 2 separate purchases totaling 273,730 shares for $359,010.19 (blended average price $1.31) on consecutive days, increasing his holdings from 13.60M to 13.88M shares. This activity occurs amid significant price deterioration—ACRS trades at $1.34, down -86.4% from its 52-week high of $9.87, though the stock has recovered +16.5% over the past 30 days. The company is burning cash operationally, having posted -$16.9M net loss in its latest period against only $2.4M quarterly revenue. Michael's 5 prior purchases at ACRS all fall within the past month (July 3–22) with outcomes not yet measurable at the 90-day horizon. His cross-ticker track record shows a 17.6% average 30-day return across 20 prior buys, though that pattern does not yet extend to his recent ACRS trades. The filing documents sustained accumulation into a distressed valuation amid ongoing operational losses.

10% Owner Braden Michael buys 154,722 shares (154.7K) across 3 transactions totaling $201,808.12 in depressed stock

Leonard Braden Michael, a 10% owner at Aclaris Therapeutics, executed 3 separate purchases totaling 154,722 shares for $201,808.12 between July 18–22, 2024, at a blended average price of $1.30. The current stock price of $1.33 sits -87.6% from its 52-week high of $10.69, indicating the company is trading at severely depressed levels. This represents a meaningful addition to his substantial 13.60M share position (a +1.2% increase). Notably, prior to this filing, Braden had executed 4 consecutive buys at ACRS in late June and early July 2024, all outcomes currently unmeasurable; however, his broader cross-ticker track record shows 20 prior open-market buys with an average 30-day return of +426.2%, though this outcome data does not yet extend to these current ACRS positions.

10% owner Leonard Braden Michael buys 352,397 shares at $1.15 avg across 3 transactions; stock down 89.0% from 52-week high despite +14.3% in 30 days

Leonard Braden Michael, a 10% owner of Aclaris Therapeutics (ACRS), executed 3 separate purchases totaling 352,397 shares for $405,894.27 at a blended average price of $1.15 across July 1–5, 2024. This represents a 2.7% increase to his existing 13.10M-share position. While the stock has rebounded +14.3% over the preceding 30 days, it remains -89.0% below its 52-week high of $10.95, trading at $1.20 currently. The company generated only $2.4M in quarterly revenue with a net loss of $16.9M and is unprofitable on a full-year basis. His cross-ticker track record shows an average 30-day return of +1187.3% across 18 prior buys; however, his same-ticker history at ACRS shows 5 prior buys with outcomes not yet measurable, establishing no pattern of timing accuracy specific to this security. The timing of these purchases in a severely depressed stock—combined with his sustained ownership stake—merits monitoring to track whether this position signals a fundamental valuation view or reflects other motivations not evident from price action alone.

10% owner Leonard Braden Michael purchased 1,543,434 shares across 4 transactions for $1,742,074.99 at ACRS, raising holdings by 13.4%

Leonard Braden Michael executed 4 separate purchases totaling 1,543,434 shares for $1,742,074.99 (blended average $1.13) over a 4-day window (2024-06-27 to 2024-07-01), increasing his stake from 11,552,138 to 13,095,572 shares. The timing is notable: these purchases occurred while the stock traded between $1.12–$1.15, well below the 52-week high of $10.95 (currently -89.5% from peak). The company is unprofitable ($-16.9M net income) with minimal quarterly revenue ($2.4M), and the stock has declined -5.7% over 90 days despite a +11.6% bounce in the past 30 days. His 5 prior purchases at ACRS since 2024-06-13 remain too recent to assess 90-day outcomes, and his cross-ticker track record (14 prior buys, avg 30d return +1187.3%) reflects historical patterns, not predictive power for this specific position in a deeply depressed equity.

10% owner Leonard Braden Michael buys 545,000 shares across 3 transactions (June 11–18) for $628,206 at blended $1.15 as ACRS trades at $1.13

Leonard Braden Michael, a 10% owner of Aclaris Therapeutics, executed 3 separate purchases totaling 545,000 shares for $628,206.00 between June 11 and June 18, 2024, at prices ranging from $1.13 to $1.17. The stock currently trades at $1.13, down 89.7% from its 52-week high of $10.95, and the company posted a quarterly revenue of $2,398,000.00 with a net loss of $16,941,000.00. The purchases occurred in a heavily depressed environment—well below the recent 52-week range—following a pattern of four consecutive buys at this ticker within a 6-day window (June 11–13). While the insider's cross-ticker track record shows 11 prior buys with an average 30-day return of +1187.3%, those outcomes are not yet measurable for the same-ticker ACRS transactions, and the insider's timing accuracy on prior ACRS trades cannot be assessed as no prior same-ticker buys have reached the 90-day measurement window. The recurring accumulation in a distressed valuation context warrants attention to the underlying business catalyst or strategic rationale behind these purchases.